Literature DB >> 21750223

Nerve growth factor links oral cancer progression, pain, and cachexia.

Yi Ye1, Dongmin Dang, Jianan Zhang, Chi T Viet, David K Lam, John C Dolan, Jennifer L Gibbs, Brian L Schmidt.   

Abstract

Cancers often cause excruciating pain and rapid weight loss, severely reducing quality of life in cancer patients. Cancer-induced pain and cachexia are often studied and treated independently, although both symptoms are strongly linked with chronic inflammation and sustained production of proinflammatory cytokines. Because nerve growth factor (NGF) plays a cardinal role in inflammation and pain, and because it interacts with multiple proinflammatory cytokines, we hypothesized that NGF acts as a key endogenous molecule involved in the orchestration of cancer-related inflammation. NGF might be a molecule common to the mechanisms responsible for clinically distinctive cancer symptoms such as pain and cachexia as well as cancer progression. Here we reported that NGF was highly elevated in human oral squamous cell carcinoma tumors and cell cultures. Using two validated mouse cancer models, we further showed that NGF blockade decreased tumor proliferation, nociception, and weight loss by orchestrating proinflammatory cytokines and leptin production. NGF blockade also decreased expression levels of nociceptive receptors TRPV1, TRPA1, and PAR-2. Together, these results identified NGF as a common link among proliferation, pain, and cachexia in oral cancer. Anti-NGF could be an important mechanism-based therapy for oral cancer and its related symptoms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21750223      PMCID: PMC3375020          DOI: 10.1158/1535-7163.MCT-11-0123

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  46 in total

1.  Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization.

Authors:  Molly A Sevcik; Joseph R Ghilardi; Christopher M Peters; Theodore H Lindsay; Kyle G Halvorson; Beth M Jonas; Kazufumi Kubota; Michael A Kuskowski; Leila Boustany; David L Shelton; Patrick W Mantyh
Journal:  Pain       Date:  2005-05       Impact factor: 6.961

Review 2.  Novel class of pain drugs based on antagonism of NGF.

Authors:  Franz F Hefti; Arnon Rosenthal; Patricia A Walicke; Sean Wyatt; German Vergara; David L Shelton; Alun M Davies
Journal:  Trends Pharmacol Sci       Date:  2005-12-27       Impact factor: 14.819

3.  Metabolic syndrome--neurotrophic hypothesis.

Authors:  M Hristova; L Aloe
Journal:  Med Hypotheses       Date:  2005-11-18       Impact factor: 1.538

4.  Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis.

Authors:  David L Shelton; Jörg Zeller; Wei-Hsien Ho; Jaume Pons; Arnon Rosenthal
Journal:  Pain       Date:  2005-07       Impact factor: 6.961

5.  Effect of a long-term nerve growth factor treatment on body weight, blood pressure, and serum corticosterone in rats.

Authors:  G Taglialatela; P J Foreman; J R Perez-Polo
Journal:  Int J Dev Neurosci       Date:  1997-10       Impact factor: 2.457

6.  Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain.

Authors:  W G Mantyh; J M Jimenez-Andrade; J I Stake; A P Bloom; M J Kaczmarska; R N Taylor; K T Freeman; J R Ghilardi; M A Kuskowski; P W Mantyh
Journal:  Neuroscience       Date:  2010-09-20       Impact factor: 3.590

7.  Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha.

Authors:  Bohan Wang; John R Jenkins; Paul Trayhurn
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-11-23       Impact factor: 4.310

8.  Serum protein markers for early detection of ovarian cancer.

Authors:  Gil Mor; Irene Visintin; Yinglei Lai; Hongyu Zhao; Peter Schwartz; Thomas Rutherford; Luo Yue; Patricia Bray-Ward; David C Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-12       Impact factor: 11.205

9.  A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone.

Authors:  Kyle G Halvorson; Kazufumi Kubota; Molly A Sevcik; Theodore H Lindsay; Julio E Sotillo; Joseph R Ghilardi; Thomas J Rosol; Leila Boustany; David L Shelton; Patrick W Mantyh
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

Review 10.  Cytokines in head and neck cancer.

Authors:  Ralph Pries; Barbara Wollenberg
Journal:  Cytokine Growth Factor Rev       Date:  2006-03-15       Impact factor: 7.638

View more
  58 in total

Review 1.  Perineural growth in head and neck squamous cell carcinoma: a review.

Authors:  Joseph Roh; Thomas Muelleman; Ossama Tawfik; Sufi M Thomas
Journal:  Oral Oncol       Date:  2014-10-25       Impact factor: 5.337

Review 2.  The transient receptor potential channel TRPA1: from gene to pathophysiology.

Authors:  Bernd Nilius; Giovanni Appendino; Grzegorz Owsianik
Journal:  Pflugers Arch       Date:  2012-09-22       Impact factor: 3.657

Review 3.  TRPA1: A gatekeeper for inflammation.

Authors:  Diana M Bautista; Maurizio Pellegrino; Makoto Tsunozaki
Journal:  Annu Rev Physiol       Date:  2012-09-27       Impact factor: 19.318

4.  Systemic Depletion of Nerve Growth Factor Inhibits Disease Progression in a Genetically Engineered Model of Pancreatic Ductal Adenocarcinoma.

Authors:  Jami L Saloman; Aatur D Singhi; Douglas J Hartman; Daniel P Normolle; Kathryn M Albers; Brian M Davis
Journal:  Pancreas       Date:  2018-08       Impact factor: 3.327

Review 5.  Exosomal Induction of Tumor Innervation.

Authors:  Paola D Vermeer
Journal:  Cancer Res       Date:  2019-05-14       Impact factor: 12.701

Review 6.  Biologic mechanisms of oral cancer pain and implications for clinical therapy.

Authors:  C T Viet; B L Schmidt
Journal:  J Dent Res       Date:  2011-10-04       Impact factor: 6.116

7.  Intrathecal administration of Resolvin D1 and E1 decreases hyperalgesia in mice with bone cancer pain: Involvement of endocannabinoid signaling.

Authors:  Iryna A Khasabova; Mikhail Y Golovko; Svetlana A Golovko; Donald A Simone; Sergey G Khasabov
Journal:  Prostaglandins Other Lipid Mediat       Date:  2020-07-31       Impact factor: 3.072

Review 8.  The neurobiology of skeletal pain.

Authors:  Patrick W Mantyh
Journal:  Eur J Neurosci       Date:  2014-02       Impact factor: 3.386

9.  Legumain Induces Oral Cancer Pain by Biased Agonism of Protease-Activated Receptor-2.

Authors:  Nguyen Huu Tu; Dane D Jensen; Bethany M Anderson; Elyssa Chen; Nestor N Jimenez-Vargas; Nicole N Scheff; Kenji Inoue; Hung D Tran; John C Dolan; Tamaryn A Meek; Morley D Hollenberg; Cheng Z Liu; Stephen J Vanner; Malvin N Janal; Nigel W Bunnett; Laura E Edgington-Mitchell; Brian L Schmidt
Journal:  J Neurosci       Date:  2020-11-10       Impact factor: 6.167

Review 10.  Review of preclinical studies on treatment of mucositis and associated pain.

Authors:  C T Viet; P M Corby; A Akinwande; B L Schmidt
Journal:  J Dent Res       Date:  2014-06-18       Impact factor: 6.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.